Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 6, 2012, Pages 316-323

  Gonçalves, José Eduardo ^a   Ballerini Fernandes, Mariane ^a   Chiann, Chang ^a   Gai, Maria Nella ^b   De Souza, Jacqueline ^c   Storpirtis, Sílvia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CHILE   (Chile)

^c FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

absorption; Caco 2 cells; intestinal permeability; rifampicin

Indexed keywords

BOVINE SERUM ALBUMIN; MUCIN; RIFAMPICIN;

ARTICLE; BASOLATERAL MEMBRANE; DONOR SITE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTESTINE MUCOSA; PH; QUALITATIVE ANALYSIS; ULTRAVIOLET RADIATION;

ANTIBIOTICS, ANTITUBERCULAR; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MUCINS; PERMEABILITY; RIFAMPIN; SERUM ALBUMIN, BOVINE; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84866241341     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1802     Document Type: Article

References (33)

1. Zhang Y,. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 2005; 45: 529-564. (Pubitemid 40261816)
2. Bacchi A, Pelizzi G, Nebuloni M, Ferrari P,. Comprehensive study on structure-activity relationships of rifamycins: Discussion of molecular and crystal structure and spectroscopic and spectroscopic and thermochemical properties of rifamycin O. J Med Chem 2008; 41: 2319-2332.
3. Gumbo T,. Chemotherapy of tuberculosis, mycobacterium avium complex disease, and leprosy. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edn, Brunton L, Chabner B, Knollman B, (eds). McGraw-Hill: New York, 2011; 1549-1570.
4. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Vora MJ,. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm 2001; 228: 53-67. (Pubitemid 32905365)
5. Singh S, Mariappan TT, Sankar R, Sarda N, Singh B,. A critical review of probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm 2001; 228: 5-17. (Pubitemid 32905361)
6. Agrawal S, Ashokraj Y, Bharatam PV, Pillai O, Panchagnula R,. Solid state characterization of rifampicin samples and its biopharmaceutic relevance. Eur J Pharm Sci 2004; 22: 127-144. (Pubitemid 38668679)
7. Panchagnula R, Bedi S, Yasvanth A,. Rifampicin: polymorphism or crystal defects. Clin Res Regul Aff 2006; 23: 71-83.
8. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Kotecha JS, Shah PB,. Stability of rifampicin in the dissolution medium in presence of isoniazid. Int J Pharmacol 1999; 190: 109-123. (Pubitemid 29467478)
9. Souza J, Freitas ZMF, Storpirtis S,. Modelos in vitro para determinação da absorção de fármacos e previsão da relação dissolução/ absorção. Braz J Pharm Sci 2007; 43: 515-527. (Pubitemid 351522695)
10. Souza J, Benet LZ, Huang Y, Storpirtis S,. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 Cell monolayers. J Pharm Sci 2009; 98: 4413-4419.
11. Gonçalves JE, Souza J, Storpirtis S,. Avaliação da permeabilidade de fármacos empregando culturas celulares. In Biofarmacotécnica-Série Ciências Farmacêuticas., Storpirtis S, et al. (eds). Guanabara Koogan: Rio de Janeiro, 2009.
12. Hidalgo IH,. Cultured intestinal epithelial cell models. In Models or Assessing Drug Absorption and Metabolism, Borchardt T, Smith PL, Wilson G, (eds). Plenum Press: New York, 1996; 35-50.
13. Hilgers AR, Conradi RA, Burton PS,. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 1990; 7: 902-910. (Pubitemid 20349761)
14. Tanaka Y, Taki Y, Sakane T, et al,. Characterization of drug transport through tight-junctional pathway in Caco-2 monolayer: comparison with isolated rat jejunum and colon. Pharm Res 1995; 12: 523-528. doi: 10.1023/A: 1016245711557.
15. Artursson P, Karlsson J,. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885.
16. Rubas W, Jezyk N, Grass GM,. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res 1993; 10: 113-118. (Pubitemid 23020847)
17. Stewart BH, Chan OH, Lu RH, et al,. Comparison of intestinal permeabilities determined in multipole in vitro and in situ models: Relationship to absorption in humans. Pharm Res 1995; 12: 693-699.
18. Chong S, Dando SA, Soucek KM, Morrison RA,. In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm Res 1996; 13: 120-123. (Pubitemid 26076307)
19. Braybrooks MP, Barry BW, Abbs E,. The effect of mucin on bioavailability of tetracycline from the gastro-intestinal tract: in vitro in vivo correlations. J Pharm Pharmacol 1974; 27: 508-515.
20. Kearney P, Marriott C,. The effect of mucus glycoproteins on the bioavailability of tetracycline: II Binding. Int J Pharm 1987; 35: 211-217. (Pubitemid 17018983)
21. Matthes I, Nimmerfall F, Sucker H,. Mucusmodelle zur untersunchung von intestinalen absorptions mechanismen. Pharmazie 1992; 47: 609-613.
22. Horter D, Dressman JB,. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 2001; 46: 75-83.
23. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H,. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cell. Eur J Pharm Sci 2000; 10: 195-204. (Pubitemid 30190095)
24. Shiah YF, Fernandez P, Jackson MJ, Mcmonagle S,. Mechanism maintaining a low-pH microclimate in the intestine. Physiology 1985; 248: 608-617.
25. Rubas W, Jezyk N, Grass GM,. Comparison of the permeability characteristic of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res 1993; 10: 113-118. (Pubitemid 23020847)
26. Matsumoto S, Saito H, Inui K,. Transcellular transport of oral cephalosporins in human intestinal epithelial cells, Caco-2: Interaction with dipeptide transport systems in apical and basolateral membranes. J Pharmacol Exp Ther 1994; 270: 498-504. (Pubitemid 24271357)
27. Maggi N, Pasqualucci CR, Ballotta R, Sensi P,. Rifampicin: a new orally active rifamycin. Chemotherapy 1966; 11: 285-292.
28. Gallo GG, Radaelli P,. Rifampicin. In Analytical Profiles of Drug Substances, Florey K, (ed.). Academic Press: London, 1976.
29. Biganzoli E, Cavenaghi LA, Rossi R, Brunati MC, Nolli ML,. Use of a Caco-2 cell culture model for the characterization of intestinal absorption of antibiotics. Farmaco 1999; 5: 594-599. (Pubitemid 29462620)
30. Krishna G, Chen KJ, Lin CC, Nomeir A,. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int J Pharm 2001; 222: 77-89. (Pubitemid 32525789)
31. Fossati L, Dechaume R, Hardillier E, et al,. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs. Int J Pharm 2008; 360: 148-155.
32. Neuhoff S, Artursson P, Zamora I, Ungell A-L,. Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells. Pharm Res 2006; 23: 350-359. (Pubitemid 43239592)
33. Acocella G,. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3: 108-127.